Matthew L. Posard sold $478K of Halozyme Therapeutics (HALO)

Executed Oct 1, disclosed Oct 2, 1 day later.

Value, as filed

$478K

4,400 sh across 2 lots

Executed

Oct 1

the trade date, as filed

Disclosed

Oct 2

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Matthew L. Posard Director profile →

Matthew L. Posard (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Halozyme Therapeutics, Inc. (HALO). The largest single filing was $2.0M of HALO (18,996 sh across 4 lots, as filed), executed Sep 16.

The name

HALO

Halozyme Therapeutics, Inc. HALO · Healthcare · 38 filings in 24 months ticker →

Healthcare · Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in th…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Matthew L. Posard in HALO

HALOSALE Halozyme Therapeutics, Inc. $2.0M
18,996 sh across 4 lots
Exec Sep 16
Filed Sep 17 · 5:19 PM ET